Deep TMS is NOT FDA-approved for bipolar depression
Deep transcranial magnetic stimulation (deep TMS) does not have FDA approval specifically for bipolar depression, and current evidence does not support its routine use for this indication. While deep TMS has been studied in bipolar depression research settings, the evidence remains insufficient and conflicting 1.
Current FDA Approval Status
Deep TMS lacks regulatory approval for bipolar depression. The available guidelines explicitly distinguish bipolar depression from unipolar major depressive disorder in treatment recommendations. Consensus guidelines specifically recommend that bipolar depression should be excluded from treatment-resistant depression (TRD) definitions and clinical trials, as it is part of bipolar disorder rather than major depressive disorder 2.
Evidence Quality and Limitations
A 2026 systematic review and meta-analysis of TMS for bipolar depression found 1:
- Small overall antidepressant effect (SMD = -0.34) compared to sham
- 88.2% of individual trials failed to show superiority over sham at the individual study level
- Effects were not consistently confirmed in sensitivity analyses by treatment type, stimulation site, or treatment resistance
- Most studies had small sample sizes (mean N = 15.4 per group)
- 65% of studies had "some concerns" regarding risk of bias
While one open-label pilot study showed encouraging response rates (87.1%) and remission rates (74.2%) with high-frequency left-sided TMS in 31 patients with bipolar depression 3, this was uncontrolled and cannot establish efficacy.
Critical Clinical Considerations
If considering TMS for bipolar depression off-label, the following are mandatory:
- Concurrent mood stabilizer treatment is essential - all patients in the pilot study were treated with mood stabilizers 3
- Lithium co-treatment was associated with higher depression scores (worse outcomes) 3
- Lamotrigine co-treatment was associated with lower depression scores (better outcomes) 3
- Monitor closely for treatment-emergent mania or hypomania
- No seizures or serious adverse events have been reported in bipolar depression studies 1
Approved Alternatives
For bipolar depression, FDA-approved pharmacological options include 4:
- Olanzapine-fluoxetine combination (approved for bipolar depression in adults)
- Lamotrigine (approved for maintenance therapy in adults)
- Quetiapine (approved for acute bipolar depression)
The evidence base for these medications, while imperfect, substantially exceeds that for deep TMS in bipolar depression.
Bottom Line
Deep TMS remains an investigational treatment for bipolar depression without regulatory approval. The meta-analytic evidence suggests only small effects that are not robust across sensitivity analyses, with most individual trials being negative. If used off-label, it must be combined with mood stabilizers (preferably lamotrigine over lithium based on available data) and patients should be informed of the limited and conflicting evidence base 1, 3.